TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Brief Summary: Inflammatory bowel disease (IBD) is a chronic, debilitating, relapsing inflammatory disorder affecting the gastrointestinal tract which does not have a medical cure. IBD consists of 2 different forms: Crohn's Disease (CD) and Ulcerative Colitis (UC). In the last 2 decades, Gut Microbial Transplantation (GMT), also known as fecal transplantation, has been used as a treatment option for Clostridium difficile colitis and UC. The literature supports strong evidence for the plausibility of using GMT for patients with IBD associated colitis, especially for patients with UC.

This research will be conducted in the Helen DeVos Children's Hospital (HDVCH) Pediatric gastrointestinal outpatient clinic. A pilot study of ten patients will be conducted to evaluate if GMT improves clinical symptoms in patients with IBD. Patients with IBD colitis (UC and CD with colonic involvement only) will be approached for GMT as a treatment option for their disease. Each subject will undergo 5 sessions (1 session/day, and not necessarily on consecutive days) of GMT within a period of 10 days. Post treatment evaluation will be done at their regularly scheduled clinic follow up.

Healthy donors \>18 years of age will be chosen by the family, inclusive of immediate family members and friends. Donors will be required to complete a screening questionnaire, provide medical history, and undergo blood and stool tests.


Options:
A: Arm Label: Fecal Microbiota Enema; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Enema | Arm Label: Normal Saline Enema; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal Saline Enema | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Enema; Assigned to Arm(s): Fecal Microbiota Enema | Intervention Type: BIOLOGICAL; Name: Normal Saline Enema; Assigned to Arm(s): Normal Saline Enema
B: Arm Label: placebo enema; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo enema | Arm Label: Fecal transplant from an unrelated donor; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal transplant | Intervention Type: OTHER; Name: Fecal transplant; Assigned to Arm(s): Fecal transplant from an unrelated donor | Intervention Type: OTHER; Name: Placebo enema; Assigned to Arm(s): placebo enema
C: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
D: Arm Label: Study Participants; Type: EXPERIMENTAL; Interventions: Drug: Gut Microbial Transplantation | Intervention Type: DRUG; Name: Gut Microbial Transplantation; Assigned to Arm(s): Study Participants

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Brief Summary: Inflammatory bowel disease (IBD) is a chronic, debilitating, relapsing inflammatory disorder affecting the gastrointestinal tract which does not have a medical cure. IBD consists of 2 different forms: Crohn's Disease (CD) and Ulcerative Colitis (UC). In the last 2 decades, Gut Microbial Transplantation (GMT), also known as fecal transplantation, has been used as a treatment option for Clostridium difficile colitis and UC. The literature supports strong evidence for the plausibility of using GMT for patients with IBD associated colitis, especially for patients with UC.

This research will be conducted in the Helen DeVos Children's Hospital (HDVCH) Pediatric gastrointestinal outpatient clinic. A pilot study of ten patients will be conducted to evaluate if GMT improves clinical symptoms in patients with IBD. Patients with IBD colitis (UC and CD with colonic involvement only) will be approached for GMT as a treatment option for their disease. Each subject will undergo 5 sessions (1 session/day, and not necessarily on consecutive days) of GMT within a period of 10 days. Post treatment evaluation will be done at their regularly scheduled clinic follow up.

Healthy donors \>18 years of age will be chosen by the family, inclusive of immediate family members and friends. Donors will be required to complete a screening questionnaire, provide medical history, and undergo blood and stool tests.


Options:
A: Arm Label: Study Participants; Type: EXPERIMENTAL; Interventions: Drug: Gut Microbial Transplantation | Intervention Type: DRUG; Name: Gut Microbial Transplantation; Assigned to Arm(s): Study Participants
B: Arm Label: Fecal microbiota transplantation; Type: EXPERIMENTAL; Interventions: Procedure: FMT | Arm Label: Traditional treatments; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: FMT; Assigned to Arm(s): Fecal microbiota transplantation
C: Arm Label: SER-109; Type: EXPERIMENTAL; Interventions: Biological: SER-109 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: SER-109; Assigned to Arm(s): SER-109 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Metronidazole+doxycylcine+terbinafine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Doxycycline, Drug: Terbinafine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Terbinafine; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: This Was a Five-year Seven-site Trial to Study the Cost-effectiveness of a Population Based Disease Management Program for Late Life Depression in Primary Care.
Brief Summary: Purpose: To determine the effectiveness of the Improving Mood-Promoting Access to Collaborative Treatment(IMPACT) collaborative care management program for late-life depression.


Options:
A: Arm Label: Collaborative depression care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): Collaborative depression care
B: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
C: Arm Label: Collaborative care; Type: EXPERIMENTAL; Interventions: Other: Collaborative care | Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Collaborative care; Assigned to Arm(s): Collaborative care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: IMPACT; Type: EXPERIMENTAL; Interventions: Other: IMPACT | Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: IMPACT; Assigned to Arm(s): IMPACT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Time Required to Remain Sitting After Spinal Anesthesia for 50% of Patients to Not Experience Hypotension
Brief Summary: Hypotension is extremely common after induction of spinal anesthesia for cesarean delivery. Anesthetic blockade of the sympathetic outflow of the spinal cord causes vasodilation, and is one cause of this hypotension. The higher the spread of the blockade will result in a higher incidence of hypotension. Injected hyperbaric medication has about 15 minutes to spread within the intrathecal space before it will be taken up by the nerve roots. The time that a patient remains in one position after medication injection will affect the spread of the resultant anesthetic block. A patient who is left sitting for a longer period of time after injection of hyperbaric medication will have a lower level of block than someone who is placed supine immediately. In this study, the investigators wish to use up down sequential analysis to determine the time period a patient should remain seated after intrathecal injection of hyperbaric bupivacaine that will result in a 50% rate of hypotension.


Options:
A: Arm Label: Prophylactic ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Normal saline (placebo) control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Prophylactic ephedrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Normal saline (placebo) control group
B: Arm Label: 2 ml bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2 ml bupivacaine | Arm Label: 1.5 ml bupivicaine.; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5 ml bupivicaine. | Intervention Type: DRUG; Name: 2 ml bupivacaine; Assigned to Arm(s): 2 ml bupivacaine | Intervention Type: DRUG; Name: 1.5 ml bupivicaine.; Assigned to Arm(s): 1.5 ml bupivicaine.
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringer's Lactate solution | Intervention Type: DRUG; Name: HES 130/0.4 (6%) in sodium chloride (solution for infusion); Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Ringer's Lactate solution; Assigned to Arm(s): Group B
D: Arm Label: Ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Phenylephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenylephrine | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Ephedrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): Phenylephrine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Time Required to Remain Sitting After Spinal Anesthesia for 50% of Patients to Not Experience Hypotension
Brief Summary: Hypotension is extremely common after induction of spinal anesthesia for cesarean delivery. Anesthetic blockade of the sympathetic outflow of the spinal cord causes vasodilation, and is one cause of this hypotension. The higher the spread of the blockade will result in a higher incidence of hypotension. Injected hyperbaric medication has about 15 minutes to spread within the intrathecal space before it will be taken up by the nerve roots. The time that a patient remains in one position after medication injection will affect the spread of the resultant anesthetic block. A patient who is left sitting for a longer period of time after injection of hyperbaric medication will have a lower level of block than someone who is placed supine immediately. In this study, the investigators wish to use up down sequential analysis to determine the time period a patient should remain seated after intrathecal injection of hyperbaric bupivacaine that will result in a 50% rate of hypotension.


Options:
A: Arm Label: Ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Phenylephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenylephrine | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Ephedrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): Phenylephrine
B: Arm Label: 2 ml bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2 ml bupivacaine | Arm Label: 1.5 ml bupivicaine.; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5 ml bupivicaine. | Intervention Type: DRUG; Name: 2 ml bupivacaine; Assigned to Arm(s): 2 ml bupivacaine | Intervention Type: DRUG; Name: 1.5 ml bupivicaine.; Assigned to Arm(s): 1.5 ml bupivicaine.
C: Arm Label: Prophylactic ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Normal saline (placebo) control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Prophylactic ephedrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Normal saline (placebo) control group
D: Arm Label: ondansetron; Type: EXPERIMENTAL; Interventions: Drug: ondansetron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ondansetron; Assigned to Arm(s): ondansetron | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breastfeeding Promotion RCT and Child Metabolic Syndrome
Brief Summary: The overall goal of the PROBIT study is to investigate the influence of a randomized breastfeeding promotion intervention designed to increase the duration and exclusivity of breastfeeding ("the breastfeeding promotion intervention") on the development of maternal and child health outcomes. The hypothesis is that randomization to the intervention will be associated with lower child adiposity, lower risk of asthma and atopy, improved lung function, and improved cognitive outcomes.


Options:
A: Arm Label: eHealth Intervention; Type: EXPERIMENTAL; Interventions: Other: eHealth Breastfeeding Co-parenting Resource | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: eHealth Breastfeeding Co-parenting Resource; Assigned to Arm(s): eHealth Intervention
B: Arm Label: visit with grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: visit without grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: no visit with grandmother; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: no visit without grandmother; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: counseling sessions; Assigned to Arm(s): visit with grandmother, visit without grandmother
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion and support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion and support; Assigned to Arm(s): Intervention
D: Arm Label: Telelactation support; Type: EXPERIMENTAL; Interventions: Behavioral: Telelactation services | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telelactation services; Assigned to Arm(s): Telelactation support

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breastfeeding Promotion RCT and Child Metabolic Syndrome
Brief Summary: The overall goal of the PROBIT study is to investigate the influence of a randomized breastfeeding promotion intervention designed to increase the duration and exclusivity of breastfeeding ("the breastfeeding promotion intervention") on the development of maternal and child health outcomes. The hypothesis is that randomization to the intervention will be associated with lower child adiposity, lower risk of asthma and atopy, improved lung function, and improved cognitive outcomes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Lactation counseling; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion and support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion and support; Assigned to Arm(s): Intervention
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Telephone Support Intervention to Improve Breastfeeding | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone Support Intervention to Improve Breastfeeding; Assigned to Arm(s): A
D: Intervention Type: BEHAVIORAL; Name: Proactive assignment to attend a breastfeeding clinic; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Complementary Food Supplements For Reducing Childhood Undernutrition: The JiVitA-4 Study
Brief Summary: The purpose of this study is to test the impact on child growth of three specially formulated complementary food supplements vs. Plumpy'Doz, a previously tested, commercially available complementary food, and vs. a control group that receives no food. All groups will receive nutrition education related to infant and young child feeding. This will be a cluster-randomised trial in children 6-18 months old in rural Rangpur and Gaibandha in Bangladesh.


Options:
A: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group
B: Arm Label: NOURISH-T; Type: EXPERIMENTAL; Interventions: Behavioral: NOURISH-T | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: NOURISH-T; Assigned to Arm(s): NOURISH-T | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
C: Arm Label: No food; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Plumpy Doz; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Plumpy Doz | Arm Label: Wheat Soy Blend (WSB++); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Wheat Soy Blend (WSB++) | Arm Label: Chickpea based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Chickpea based complementary food supplement | Arm Label: Rice based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat Soy Blend (WSB++); Assigned to Arm(s): Wheat Soy Blend (WSB++) | Intervention Type: DIETARY_SUPPLEMENT; Name: Chickpea based complementary food supplement; Assigned to Arm(s): Chickpea based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Rice based complementary food supplement; Assigned to Arm(s): Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz; Assigned to Arm(s): Plumpy Doz
D: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Complementary Food Supplements For Reducing Childhood Undernutrition: The JiVitA-4 Study
Brief Summary: The purpose of this study is to test the impact on child growth of three specially formulated complementary food supplements vs. Plumpy'Doz, a previously tested, commercially available complementary food, and vs. a control group that receives no food. All groups will receive nutrition education related to infant and young child feeding. This will be a cluster-randomised trial in children 6-18 months old in rural Rangpur and Gaibandha in Bangladesh.


Options:
A: Arm Label: parent-targeted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multi-component/setting parent-targeted intervention | Arm Label: Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: multi-component/setting parent-targeted intervention; Assigned to Arm(s): parent-targeted intervention
B: Arm Label: Lunch in the Bag Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lunch is in the Bag behavioral intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lunch is in the Bag behavioral intervention; Assigned to Arm(s): Lunch in the Bag Intervention
C: Arm Label: No food; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Plumpy Doz; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Plumpy Doz | Arm Label: Wheat Soy Blend (WSB++); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Wheat Soy Blend (WSB++) | Arm Label: Chickpea based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Chickpea based complementary food supplement | Arm Label: Rice based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat Soy Blend (WSB++); Assigned to Arm(s): Wheat Soy Blend (WSB++) | Intervention Type: DIETARY_SUPPLEMENT; Name: Chickpea based complementary food supplement; Assigned to Arm(s): Chickpea based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Rice based complementary food supplement; Assigned to Arm(s): Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz; Assigned to Arm(s): Plumpy Doz
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: KAN-DO | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: KAN-DO | Intervention Type: BEHAVIORAL; Name: KAN-DO; Assigned to Arm(s): 1, 2

Answer: C